Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea

References

• Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat. 2018;50(2):303–316.
   PubMed Web of Science ®Google Scholar
• Korea Central Cancer Registry and National Cancer Center. Annual report of cancer statistics in Korea in 2015. http://ncc.re.kr/downloadByFileUrl.ncc?path=/downloadFiles/eng/Annual2017.
   Google Scholar
• Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:469251.
   PubMedGoogle Scholar
• NCCN. NCCN Clinical practice guidelines in oncology: Breast Cancer. Version 1.2018 – March 20, 2018.
   Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Rugo HS, Im SA, et al. Overall survival with palbociclib and fulvestrant in women with HR+/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase 3 randomized study. Clin Cancer Res. 2022;2022;clincanres.0305.2022.
   Google Scholar
• Johnston S, Martin M, Leo AD, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Jr., Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. Sep 1
   PubMed Web of Science ®Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(–) metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–5224.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Tolaney SM, Cortés J, et al. Abstract CT044: MONARCH 1: final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. Cancer Research. 2017;77(13_Supplement):CT044–CT44.
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547.
   PubMed Web of Science ®Google Scholar
• Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia SKL, et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). J Clin Oncol. 2021;39(15_suppl):1001–1001.
   PubMed Web of Science ®Google Scholar
• Lee KS, Chang HS, Lee SM, et al. Economic burden of cancer in Korea during 2000–2010. Cancer Res Treat. 2015;47(3):387–398.
   PubMed Web of Science ®Google Scholar
• Kim YA, Lee YR, Park J, et al. Socioeconomic burden of cancer in korea from 2011 to 2015. Cancer Res Treat. 2020;52(3):896–906.
   PubMed Web of Science ®Google Scholar
• Park SK, Park JA, Yang SY, et al. The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data. Curr Med Res Opin. 2020;36(11):1825–1833.
   PubMed Web of Science ®Google Scholar
• Kim SH, Jo MW, Ock M, et al. Estimation of health state utilities in breast cancer. Patient Prefer Adherence. 2017;11:531–536.
   PubMed Web of Science ®Google Scholar
• Han A, Lee KE, Lee HK, et al. Meeting highlights: the first korean breast cancer treatment consensus conference. J Breast Cancer. 2014;17(4):308–313.
   PubMed Web of Science ®Google Scholar
• Lee S, Park IH, Park S, et al. Meeting highlights: the second consensus conference for breast cancer treatment in korea. J Breast Cancer. 2017;20(3):228–233.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. Palbociclib or ribociclib in First-Line treatment in patients with hormone receptor-positive/human epidermal receptor 2-negative advanced or metastatic breast cancer? A perspective based on pharmacologic costs. Clin Breast Cancer. 2019;19(4):e519–e521.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. J Oncol Pharm Pract. 2020;26(6):1486–1491.
   PubMed Web of Science ®Google Scholar
• Lee JE, Shin HI, Do YK, et al. Catastrophic health expenditures for households with disabled members: evidence from the korean health panel. J Korean Med Sci. 2016;31(3):336–344.
   PubMed Web of Science ®Google Scholar
• Shin SM, Lee HW. Comparison of out-of-pocket expenditure and catastrophic health expenditure for severe disease by the health security system: based on end-stage renal disease in South Korea. Int J Equity Health. 2021;20(1):6.
   PubMed Web of Science ®Google Scholar